Endpoints
Tumors, SD
DISEASE, SECONDARY, TUMORS
The primary endpoint was the safety and tolerability of LXI-15029 monotherapy, including confirmation of MTD. The secondary endpoints were the PK parameters and investigator-assessed antitumor effect, including objective response rate (ORR, defined as the proportion of patients with complete response [CR] and partial response [PR] as the best overall response), disease control rate (DCR, defined as the proportion of patients with CR, PR or stable disease [SD] ≥ 6 weeks) and progression-free survival (PFS) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.